Cabozantinib and selumetinib for plexiform neurofibromas
Treatments studied
Part of Brain & nervous system, Cancer, Genetic & congenital clinical trials.
This trial tests a combination of two targeted drugs (cabozantinib and selumetinib) for people with NF1 who have plexiform neurofibromas that are growing or causing significant problems. The goal is to see if this combination can shrink or slow the growth of these tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Diagnosis of NF1 (neurofibromatosis type 1)
- Plexiform neurofibroma that is growing or causing symptoms like pain, disfigurement, or loss of function
- Age 16 or older
- Tumor visible on MRI and at least 3 mL in volume (about the size of a grape)
- Adequate kidney, liver, bone marrow, and thyroid function
- Must not have certain other cancers or have completed prior cancer treatments
- Must not be pregnant or breastfeeding, and must use effective contraception during and for 4 months after treatment
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether the drug selumetinib can prevent the growth of plexiform neurofibromas (nerve tumors) in young children with NF1. Children are first monitored with MRI scans, and if a tumor appears or grows, they may receive treatment.
This trial tests a capsule medication (smetinib) for people with type 1 neurofibromatosis (NF1) who have tumors that can be surgically removed but have not spread to vital areas like the brain or spine. The goal is to see if the drug can help shrink or control these tumors.
This trial tests a new pill (smeitinib) to shrink tumors caused by neurofibromatosis type 1 (NF1). It is for adults with NF1 who have tumors that cannot be removed by surgery, including those that press on the brain or spine.
This trial studies whether the medicine abemaciclib can shrink or slow the growth of “atypical neurofibromas” in people with NF1. Participants take pills and undergo regular check-ups, including MRI scans to measure the tumor.
This Phase 2 trial tests HL-085 in adults with neurofibromatosis type 1 (NF1) who have a nerve tumor (plexiform neurofibroma) that cannot be removed by surgery and causes symptoms. It aims to shrink or control the tumor by measuring changes on MRI and monitoring side effects.
This trial tests an oral capsule called TQ-B3234 for adults who have painful, inoperable nerve tumors from neurofibromatosis type 1. It aims to see if the drug can shrink these tumors or stop them from growing.
Hear when a new Neurofibromatosis 1 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.